Market Cap 405.53B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.65
Forward PE 21.86
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 8,017,500
Avg Vol 6,109,314
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 85%
Beta 0.50
Analysts Strong Sell
Price Target $244.54

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
PrivateProfiteering
PrivateProfiteering Nov. 22 at 1:40 AM
$ABBV: The current market context shows a strong upward momentum with the last close at $236.28. The RSI at 83.59 indicates that the stock is overbought, suggesting a potential pullback. The MA30 and MA50 are both below the current price, indicating a bullish trend, but the high RSI signals caution. Directional bias is mixed; while the stock is in an uptrend, the high RSI suggests a correction may be imminent. The 60D high is $244.81, which could serve as a resistance level, while the 60D low of $207.61 provides a support reference. Suggested entry: Consider waiting for a pullback to around $230. Stop loss: $225. Targets: First target at $240 (near 60D high) and second target at $244.81 (60D high). Monitor RSI and price action closely for confirmation of entry and exit points. https://privateprofiteers.com
0 · Reply
kp570
kp570 Nov. 21 at 11:13 PM
$ABBV I love this monster. Average of 136, I don’t add, sell, or even look really at it. Just DRIP n chill
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 10:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $235.00 Put · NOV 28, 2025 Exp Entry Price: $2.33 - $2.58 Exit Price Target: $4.47 Profit Margin: +92% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Skol_ball
Skol_ball Nov. 21 at 8:46 PM
$ABBV nice
0 · Reply
JFDI
JFDI Nov. 21 at 8:44 PM
0 · Reply
Iightning
Iightning Nov. 21 at 8:22 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 21 at 8:01 PM
$SLS $225M Market Cap about to release Phase 3 Registrational trial Results worth $25B to Big Pharma. - A positive P3 result will Give Gps the FDA green light to treat 25,000 AML remission patients - and Generate Billions annually - Billions of Real Dollars that are worth Tens of Billions to Big Pharma. Since the IDMC Unblinded Actual Phase 3 MOS and IR Interim Data: - Institutional FUNDS Invested in SLS increased to 156, up from 39 - Share Price is Up 50% - SLS Market Value is Up over 300% from $77M to $215M - Cash on Hand is Up from just $13M to $74M / .50 /share - Runway into 2028 UNBLINDED MOS and IR DATA that told everyone who knows, its GPs. Gps is the reason we are STILL waiting. $ABBV and $BMY know its not Aza VEN causing the near miraculous ALL Pooled MOS Numbers... VIALE-M FAILED - VIALE-T FAILED - VERONA FAILED ... It's GPs doing what its done in all Previous Trials, Prevent Relapse and Extend Survival.
0 · Reply
kagrawala
kagrawala Nov. 21 at 7:03 PM
$ABBV just a class act - abbv is top tier - long since 2018
0 · Reply
crtlabz
crtlabz Nov. 21 at 6:54 PM
$ABBV just beautiful!
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 21 at 6:52 PM
In the 4 weeks since $BIIB announced “up to” $1.1b in pre clinical C5aR inhibitor Vanqua, it’s added $35 / share of value. With 145m shares outstanding, it’s added $4.5b in 4 weeks since beefing up their CNS / Alzheimer’s/ under disguise of building “I&I” biz. Wonder if anyone else can match this shareholder ROI The only other public 100% focused C5aR entity being $100M valued $IFRX. It won’t stay independent very much longer. Avacopan another gem for $AMGN aside from liver tox. Will it be Amgen to “right a wrong” or $ABBV $RHHBY to pipeline (a verb)?
2 · Reply
Latest News on ABBV
AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 9 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 10 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 13 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 20 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 21 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 21 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 21 days ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 21 days ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 23 days ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 24 days ago

AbbVie: Deep Discount Before Earnings


AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 7 weeks ago

AbbVie expects $2.7 billion R&D charge in third quarter


AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 7 weeks ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps


ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 7 weeks ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK


AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 7 weeks ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call


Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 7 weeks ago

Natrelle® Awarded Supplier Agreement from Vizient


AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 7 weeks ago

AbbVie For Healthy Dividend Growth


PrivateProfiteering
PrivateProfiteering Nov. 22 at 1:40 AM
$ABBV: The current market context shows a strong upward momentum with the last close at $236.28. The RSI at 83.59 indicates that the stock is overbought, suggesting a potential pullback. The MA30 and MA50 are both below the current price, indicating a bullish trend, but the high RSI signals caution. Directional bias is mixed; while the stock is in an uptrend, the high RSI suggests a correction may be imminent. The 60D high is $244.81, which could serve as a resistance level, while the 60D low of $207.61 provides a support reference. Suggested entry: Consider waiting for a pullback to around $230. Stop loss: $225. Targets: First target at $240 (near 60D high) and second target at $244.81 (60D high). Monitor RSI and price action closely for confirmation of entry and exit points. https://privateprofiteers.com
0 · Reply
kp570
kp570 Nov. 21 at 11:13 PM
$ABBV I love this monster. Average of 136, I don’t add, sell, or even look really at it. Just DRIP n chill
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 10:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $235.00 Put · NOV 28, 2025 Exp Entry Price: $2.33 - $2.58 Exit Price Target: $4.47 Profit Margin: +92% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Skol_ball
Skol_ball Nov. 21 at 8:46 PM
$ABBV nice
0 · Reply
JFDI
JFDI Nov. 21 at 8:44 PM
0 · Reply
Iightning
Iightning Nov. 21 at 8:22 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 21 at 8:01 PM
$SLS $225M Market Cap about to release Phase 3 Registrational trial Results worth $25B to Big Pharma. - A positive P3 result will Give Gps the FDA green light to treat 25,000 AML remission patients - and Generate Billions annually - Billions of Real Dollars that are worth Tens of Billions to Big Pharma. Since the IDMC Unblinded Actual Phase 3 MOS and IR Interim Data: - Institutional FUNDS Invested in SLS increased to 156, up from 39 - Share Price is Up 50% - SLS Market Value is Up over 300% from $77M to $215M - Cash on Hand is Up from just $13M to $74M / .50 /share - Runway into 2028 UNBLINDED MOS and IR DATA that told everyone who knows, its GPs. Gps is the reason we are STILL waiting. $ABBV and $BMY know its not Aza VEN causing the near miraculous ALL Pooled MOS Numbers... VIALE-M FAILED - VIALE-T FAILED - VERONA FAILED ... It's GPs doing what its done in all Previous Trials, Prevent Relapse and Extend Survival.
0 · Reply
kagrawala
kagrawala Nov. 21 at 7:03 PM
$ABBV just a class act - abbv is top tier - long since 2018
0 · Reply
crtlabz
crtlabz Nov. 21 at 6:54 PM
$ABBV just beautiful!
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 21 at 6:52 PM
In the 4 weeks since $BIIB announced “up to” $1.1b in pre clinical C5aR inhibitor Vanqua, it’s added $35 / share of value. With 145m shares outstanding, it’s added $4.5b in 4 weeks since beefing up their CNS / Alzheimer’s/ under disguise of building “I&I” biz. Wonder if anyone else can match this shareholder ROI The only other public 100% focused C5aR entity being $100M valued $IFRX. It won’t stay independent very much longer. Avacopan another gem for $AMGN aside from liver tox. Will it be Amgen to “right a wrong” or $ABBV $RHHBY to pipeline (a verb)?
2 · Reply
mj_ryder
mj_ryder Nov. 21 at 6:47 PM
$ABBV all healthcare running with with $SPY $SPX recovering for reversal where 660 is strong. $NVDA seems bottom out for this week, 180 holding well. ABBV needs to break and hold 238.3+ we can see $240 easily today.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 21 at 4:24 PM
$SLS Since the IDMC Unblinded Actual Phase 3 MOS and IR Interim Data: - Institutional FUNDS Invested in SLS increased to 156, up from 39 - Share Price is Up 50% - SLS Market Value is Up over 300% from $77M to $215M - Cash on Hand is Up from just $13M to $74M / .50 /share - Runway into 2028 UNBLINDED MOS and IR DATA that told everyone who knows, its GPs. Gps is the reason we are STILL waiting. $ABBV and $BMY know its not Aza VEN causing the near miraculous ALL Pooled MOS Numbers... VIALE-M FAILED VIALE-T Failed VERONA FAILED ... It's GPs doing what its done in all Previous Trials, Prevent Relapse and Extend Survival.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 21 at 4:06 PM
$SLS @jhk35611 -- There's been so much disinformation and Fud here, definitely contributes to this being the Investment Opportunity of a Lifetime. - we have a Truly Imminent Phase 3 Registrational Trial result that will give Gps the Fda authority to treat tens of thousands of AML patients each year, and generate Billions of Dollars in Real Revenue - which in turn is worth Tens of Billions to large pharma's. ... exciting days. Since the IDMC Unblinded Actual Phase 3 MOS and IR Interim Data: Institutional FUNDS increased to 156, up from 39 Share Price is Up 50% Market Value is Up over 300% from $77M to $215M Cash on Hand is Up from just 13m to $74M / .50 /share Runway into 2028 UNBLINDED MOS and IR DATA that told everyone who knows, its GPs. Gps is the reason we are STILL waiting. $ABBV and $BMY know its not Aza VEN causing the near miraculous ALL Pooled MOS Numbers... VIALE-M FAILED VIALE-T Failed VERONA FAILED ... .. ..
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 21 at 2:58 PM
$ABBV spot on-this is going past $250
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 21 at 1:58 PM
0 · Reply
Quantumup
Quantumup Nov. 21 at 1:11 PM
Jefferies🏁 $MPLT Buy/$32 KRTX - $BMY CERE - $ABBV $NBIX Jefferies said in its initiation—MPLT has an intriguing Phase II pipeline that could ultimately disrupt the CNS/neuro landscape, starting with ML-007C-MA (oral M1/M4 agonist) in schizophrenia (SCZ) and Alzheimer's disease psychosis (ADP). Second asset ML-004 is an oral 5-HT1B/1D for autism spectrum disorder (ASD). Each program represents a $1B+ blockbuster opportunity, and all of them will have pbo-controlled Phase II data in 2026-27 (3 shots on goal). As such, we like the risk/reward at $660M cap, since $1B+ in peak sales (conservative) x low 2-3x multiple = $2-3B of value per program (unadjusted), which could be quickly realized over the next 1-2 years. Also, ML-007's program success could attract Big Pharma attention. Muscarinics in SCZ alone have been a high-value target, as evidenced by two major M&A deals with $14B+ for BMY/KRTX (Cobenfy) and $9B for ABBV/CERE (emracladiine).
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 21 at 2:06 AM
$ABBV: The last close at $229.93 indicates a strong position within its recent trading range. With an RSI of 67.01, the stock is approaching overbought territory, suggesting a potential pullback. The 30-day MA at $226.77 and the 50-day MA at $226.39 provide support levels, indicating a bullish trend in the short term. The 60-day high of $244.81 sets a target for upward momentum, while the low of $205.49 establishes a solid floor for risk management. Directional bias: Slightly bullish, but caution is warranted due to the high RSI. Suggested entry: $229.00 (on a slight pullback). Stop: $225.00 (below the 30-day MA). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for potential reversal signals as the stock approaches overbought conditions. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 21 at 12:19 AM
Bought $ABBV at $229.45. From Grok: "Uptrend confirmed (price>EMA>SMA, both rising), bouncing off rising supports at $216-220 post-earnings dip with bullish MACD/RSI neutral; favorable R/R targeting $235 resistance. Next earnings ~Jan 31, 2026; no catalysts next 3 days." https://www.techtrader.ai/grokwall/?post=15613&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Iightning
Iightning Nov. 20 at 11:12 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 10:54 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $227.50 Put · NOV 28, 2025 Exp Entry Price: $2.38 - $2.45 Exit Price Target: $3.58 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
TripleGateCptl
TripleGateCptl Nov. 20 at 10:15 PM
$ALDX Todd is bringing up CLIMATE CHANGE to hype Reproxalap in allergy, lol It’s pure comedy and you people are eating up like he hasnt already gotten rejected twice the funny thing is, $ABBV and $ALDX are hyping the drug based on the data that got them the first CRL. RENEW Part 1 disaster funny
2 · Reply
TechTraderGrok
TechTraderGrok Nov. 20 at 10:06 PM
Bought $ABBV at $229.81. From Grok: "Entering long ABBV in confirmed uptrend with price above rising EMA/SMA, positive MACD crossover signaling momentum, recent bounce from $212 support amid pharma sector strength and no imminent catalysts, targeting multi-week hold towards $235 resistance." https://www.techtrader.ai/grokwall/?post=15600&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply